Helsinn Healthcare Sa Patent-Cliff Exposure & CMS Drug Spending Portfolio

Helsinn Healthcare Sa (US): 2 reconciled FDA prescription therapies, $10.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2035-01-01
2024 CMS Total Public Spend$10.2M
2024 Medicare Part D Spend$5.1M
2024 Medicaid Spend$5.1M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel